Table I.
Summary of brain metastasis development among different cancer cell lines in athymic rats.
| Cancer type | Cell line | αV integrin1 | Metastasis incidence2 | Tumor no.3 | Tumor vol.4 | Survival5(d) |
|---|---|---|---|---|---|---|
| Lung carcinoma | ||||||
| Small cell | LX1 | Medium | 3/30 (10%) | 1±0 | 0.1–78 | 36 |
| H146 | Low-medium | 0/4 (0%) | 0 | 0 | – | |
| DMS79 | Low | 0/4 (0%) | 0 | 0 | – | |
| Non-small | H460 | High | 4/4 (100%) | 13±6 | 0.05–55 | 34 |
| H2126 | Medium-high | 0/4 (0%) | 0 | 0 | – | |
| A549 | High | 6/6 (100%) | 9±5 | 0.05–126 | 62 | |
| H520 | Low | 0/4 (0%) | 0 | 0 | – | |
| Melanoma | A375 | Low | 3/4 (75%) | 1±0 | 3.2–63 | 67 |
| A2058 | High | 4/4 (100%) | 140±70 | 0.05–7.8 | 29 | |
| A20586 | High | 14/14 (100%) | 96±66 | 0.02–24 | – | |
| Breast cancer | MDA-MB-231BR-HER2 | High | 9/9 (100%) | 15±9 | 91–316 | 52 |
Brain metastases were produced by intra-carotid infusion of 106 human cancer cells in nude rats pre-treated intraperitoneally with cyclophosphamide (100 mg/kg) 1 day before and 14 days after cell inoculation.
Cancer cell αv integrin level was measured by immunoblotting after normalization with β-tubulin.
Brain metastasis incidence was calculated by no. of rats with brain metastasis/no. of rat injected.
Number of tumors per brain in rats with brain metastases is indicated as mean±SD.
Tumor volume indicates range in mm3.
Survival (mean day after cell infusion) is shown for animals that were euthanized at 20% body weight loss for tumor burden; all non-tumor bearing rats were euthanized at 84 days after cell infusion or 3 weeks post infusion in A2058 melanoma.
105 A2058 melanoma cells were given by intra-carotid infusion.